Furthermore, DPP-4 inhibitors [7], such as sitagliptin and vildagliptin, are employed to treat type-2 diabetes as orally effective incretin (both GLP-1 and GIP) enhancers. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.